valsartan has been researched along with Arrhythmias, Cardiac in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (4.17) | 29.6817 |
| 2010's | 13 (54.17) | 24.3611 |
| 2020's | 10 (41.67) | 2.80 |
| Authors | Studies |
|---|---|
| Acosta, J; Berruezo, A; Bosch, X; Jáuregui, B | 1 |
| Belarte-Tornero, LC; Farré, N; Mojón, D | 1 |
| Castagno, D; Curtain, JP; Desai, AS; Docherty, KF; Jackson, AM; Jhund, PS; Lefkowitz, MP; McMurray, JJV; Packer, M; Petrie, MC; Rohde, LE; Rouleau, JL; Shen, L; Solomon, SD; Swedberg, K; Zile, MR | 1 |
| Gao, M; Gong, L; Wang, X; Wang, Z; Wei, Z; Zhang, M; Zhang, Q; Zhang, Z | 1 |
| Chang, HY; Chiou, WR; Chung, FP; Hsu, CY; Huang, HT; Huang, JL; Lee, YH; Liang, HW; Liao, CT; Lin, PL; Lin, WY | 1 |
| Bernard, ML; Dominic, P; Elise Hiltbold, A; Huang, E; Khatib, S; Morin, DP; Polin, GM; Rogers, PA | 1 |
| Ayesta, A; Datino, T; Díez-Villanueva, P; Esteban-Fernández, A; Jimenez-Mendez, C; Martínez-Sellés, M; Pérez, Á | 1 |
| Acquaro, M; Ghio, S; Greco, A; Pasotti, B; Rordorf, R; Sanzo, A; Savastano, S; Scelsi, L; Schirinzi, S; Seganti, A; Spolverini, M; Turco, A | 1 |
| Balsam, P; Dąbrowski, R; Farkowski, MM; Gackowski, A; Grabowski, M; Jędrzejczyk-Patej, E; Kalarus, Z; Leszek, P; Nessler, J; Opolski, G; Ozierański, K; Przybylski, A; Sterliński, M | 1 |
| Castiello, A; Gavazzoni, M; Metra, M; Sciatti, E; Vizzardi, E | 1 |
| Chang, PC; Chou, CC; Chu, Y; Huang, YC; Lee, HL; Lin, SF; Wen, MS; Wo, HT | 1 |
| Abete, R; De Ponti, R; Iacovoni, A; Marazzato, J; Mortara, A; Senni, M; Vecchi, AL | 1 |
| Chang, SL; Chen, SA; Cheng, WH; Liu, SH; Lo, LW; Lugtu, IC | 1 |
| Chiu, MH; Howlett, JG; Kuriachan, VP; Sharma, NC | 1 |
| Bayes-Genis, A; Sarrias, A | 1 |
| Ceyssens, W; Dupont, M; Luwel, E; Martens, P; Mullens, W; Nuyens, D; Rivero-Ayerza, M; Van Herendael, H; Vercammen, J | 1 |
| Bruña, V; Devesa, C; Fernández-Avilés, F; Juárez, M; Martinez-Sellés, M; Sousa-Casasnovas, I; Vicent, L | 1 |
| Ambrosio, G; Anker, SD; Díez, J; Edelmann, F; Filippatos, GS; Fraser, AG; Gavazzi, A; Gheorghiade, M; Guazzi, M; Hummel, SL; Lam, CS; Levy, D; Maggioni, AP; Metra, M; Paulus, WJ; Pfeffer, MA; Pieske, BM; Senni, M; Smiseth, OA; Solomon, SD; Stewart Coats, AJ; Stough, WG; Tschöpe, C | 1 |
| Chen, JH; Chen, LL; Chen, XH; Fu, FY; Tang, MR; Wang, WW; Zhang, FL | 1 |
| Gong, C; Huang, JF; Huang, SL; Jiang, XJ; Luo, M; Zhang, ZF; Zhao, Y | 1 |
| Chen, J; Huang, L; Le, X; Meng, J; Tang, Y; Wang, M; Wu, P; Yu, P | 1 |
| Chen, C; Le, X; Sun, S; Tang, Y; Wang, M; Yin, Y | 1 |
| Chen, RH; Jiao, KL; Li, YG; Yu, Y; Zhang, PP | 1 |
| Käser, L; Kolyvanos Naumann, U; Vetter, W | 1 |
5 review(s) available for valsartan and Arrhythmias, Cardiac
| Article | Year |
|---|---|
A narrative review on sacubitril/valsartan and ventricular arrhythmias.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Arrhythmias, Cardiac; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left | 2022 |
Sacubitril/valsartan: An antiarrhythmic drug?
Topics: Angiotensin Receptor Antagonists; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2022 |
Do Elderly Patients with Heart Failure and Reduced Ejection Fraction Benefit from Pharmacological Strategies for Prevention of Arrhythmic Events?
Topics: Aged; Angiotensin Receptor Antagonists; Arrhythmias, Cardiac; Biphenyl Compounds; Death, Sudden, Cardiac; Drug Combinations; Heart Failure; Humans; Prognosis; Stroke Volume; Tetrazoles; Valsartan | 2023 |
Ventricular arrhythmias and ARNI: is it time to reappraise their management in the light of new evidence?
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Arrhythmias, Cardiac; Biphenyl Compounds; Heart Failure; Humans; Receptors, Angiotensin; Stroke Volume; Tetrazoles; Valsartan | 2022 |
New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes.
Topics: Aminobutyrates; Anemia; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Arrhythmias, Cardiac; Biphenyl Compounds; Cardiotonic Agents; Clinical Trials as Topic; Diabetic Angiopathies; Diuretics; Drug Combinations; Exercise Therapy; Heart Failure; Homeostasis; Humans; Hypertension, Pulmonary; Iron Deficiencies; Mineralocorticoid Receptor Antagonists; Molecular Targeted Therapy; Obesity; Observational Studies as Topic; Patient Selection; Phenotype; Phosphodiesterase 5 Inhibitors; Sodium Channel Blockers; Stroke Volume; Tetrazoles; Valsartan; Vascular Stiffness | 2014 |
2 trial(s) available for valsartan and Arrhythmias, Cardiac
| Article | Year |
|---|---|
Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Arrhythmias, Cardiac; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2022 |
Effects of combined therapy of Xuezhikang Capsule and Valsartan on hypertensive left ventricular hypertrophy and heart rate turbulence.
Topics: Administration, Oral; Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Capsules; Combined Modality Therapy; Drug Combinations; Drugs, Chinese Herbal; Female; Heart Rate; Humans; Hypertension; Hypertrophy, Left Ventricular; Hypolipidemic Agents; Integrative Medicine; Male; Medicine, Chinese Traditional; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2010 |
17 other study(ies) available for valsartan and Arrhythmias, Cardiac
| Article | Year |
|---|---|
"Echocardiographic response" to sacubitril-valsartan: does it decrease defibrillation implantation, as well as the incidence of malignant arrhythmias?
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Arrhythmias, Cardiac; Biphenyl Compounds; Drug Combinations; Echocardiography; Heart Failure; Humans; Incidence; Stroke Volume; Tetrazoles; Valsartan | 2022 |
"Echocardiographic response" to sacubitril-valsartan: does it decrease defibrillation implantation, as well as the incidence of malignant arrhythmias? Response.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Arrhythmias, Cardiac; Biphenyl Compounds; Drug Combinations; Echocardiography; Heart Failure; Humans; Incidence; Stroke Volume; Tetrazoles; Valsartan | 2022 |
Clinical impacts of sacubitril/valsartan on patients eligible for cardiac resynchronization therapy.
Topics: Arrhythmias, Cardiac; Bundle-Branch Block; Cardiac Resynchronization Therapy; Electrocardiography; Heart Failure; Humans; Stroke Volume; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2022 |
Sacubitril/valsartan effects on arrhythmias and left ventricular remodelling in heart failure: An observational study.
Topics: Angiotensin Receptor Antagonists; Arrhythmias, Cardiac; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tachycardia, Ventricular; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2023 |
The effect of sacubitril / valsartan on the occurrence of ventricular arrhythmia and the risk of sudden cardiac death in patients with chronic heart failure with reduced left ventricular ejection fraction. Expert opinion of the Heart Rhythm and Heart Fail
Topics: Aminobutyrates; Arrhythmias, Cardiac; Biphenyl Compounds; Cardiology; Death, Sudden, Cardiac; Drug Combinations; Female; Heart Failure; Humans; Male; Poland; Societies, Medical; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2019 |
The potential antiarrhythmic properties of sacubitril/valsartan: a case report.
Topics: Aged; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Biphenyl Compounds; Drug Combinations; Heart Failure; Heart Rate; Humans; Male; Neprilysin; Protease Inhibitors; Recovery of Function; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left | 2019 |
LCZ696 Therapy Reduces Ventricular Tachyarrhythmia Inducibility in a Myocardial Infarction-Induced Heart Failure Rat Model.
Topics: Aminobutyrates; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Biphenyl Compounds; Disease Models, Animal; Drug Combinations; ERG1 Potassium Channel; Female; Heart Failure; Heart Rate; Heart Ventricles; Male; Myocardial Infarction; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channels, Voltage-Gated; Rats, Sprague-Dawley; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2019 |
Effects of Angiotensin Receptor-Neprilysin Inhibitor in Arrhythmogenicity Following Left Atrial Appendage Closure in an Animal Model.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Arrhythmias, Cardiac; Atrial Appendage; Atrial Natriuretic Factor; Biphenyl Compounds; Drug Combinations; Heart Atria; Models, Animal; Neprilysin; Rabbits; Septal Occluder Device; Treatment Outcome; Valsartan | 2021 |
A Case of Palpitations Due to T-Wave Oversensing Caused by Sacubitril/Valsartan.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Arrhythmias, Cardiac; Biphenyl Compounds; Drug Combinations; Electrocardiography; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Stroke Volume; Tetrazoles; Valsartan | 2018 |
Is Sacubitril/Valsartan (Also) an Antiarrhythmic Drug?
Topics: Aminobutyrates; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Biphenyl Compounds; Death, Sudden, Cardiac; Drug Combinations; Heart Failure; Heart Rate; Humans; Risk Factors; Tetrazoles; Treatment Outcome; Valsartan | 2018 |
Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Arrhythmias, Cardiac; Belgium; Biphenyl Compounds; Death, Sudden, Cardiac; Drug Combinations; Female; Follow-Up Studies; Heart Failure; Humans; Incidence; Male; Neprilysin; Retrospective Studies; Stroke Volume; Survival Rate; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2019 |
Clinical Profile and Ventricular Arrhythmias after Sacubitril/Valsartan Initiation.
Topics: Aminobutyrates; Arrhythmias, Cardiac; Biphenyl Compounds; Drug Combinations; Humans; Tetrazoles; Valsartan | 2019 |
Telmisartan reduces atrial arrhythmia susceptibility through the regulation of RAS-ERK and PI3K-Akt-eNOS pathways in spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Apoptosis; Arrhythmias, Cardiac; Atrial Remodeling; Benzimidazoles; Benzoates; Blood Pressure; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Fibrosis; Heart Rate; Hypertension; Male; Myocytes, Cardiac; Nitric Oxide Synthase Type III; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; ras Proteins; Rats, Inbred SHR; Rats, Inbred WKY; Signal Transduction; Telmisartan; Time Factors; Valsartan | 2015 |
Antioxidant and cardioprotective effects of Danshensu (3-(3, 4-dihydroxyphenyl)-2-hydroxy-propanoic acid from Salvia miltiorrhiza) on isoproterenol-induced myocardial hypertrophy in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Arrhythmias, Cardiac; Cardiomegaly; Cardiotonic Agents; Connexins; Drug Evaluation, Preclinical; Drugs, Chinese Herbal; Electrocardiography; Hemodynamics; Isoproterenol; Lactates; Male; Phytotherapy; Rats; Rats, Sprague-Dawley; Salvia miltiorrhiza; Tetrazoles; Valine; Valsartan | 2011 |
Cardiovascular protection with danshensu in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Arrhythmias, Cardiac; Blood Pressure; Body Weight; Cardiotonic Agents; Cardiovascular System; Chronic Disease; Drug Administration Schedule; Drug Evaluation, Preclinical; Heart; Heart Function Tests; Hypertension; Lactates; Large-Conductance Calcium-Activated Potassium Channels; Male; Mesenteric Arteries; Molecular Targeted Therapy; Muscle, Smooth, Vascular; Nitric Oxide Synthase Type II; Patch-Clamp Techniques; Phytotherapy; Plant Preparations; Plant Roots; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Salvia miltiorrhiza; Tetrazoles; Valine; Valsartan | 2011 |
Effects of valsartan on ventricular arrhythmia induced by programmed electrical stimulation in rats with myocardial infarction.
Topics: Animals; Arrhythmias, Cardiac; Connexin 43; Down-Regulation; Electric Stimulation; Female; Myocardial Infarction; Rats; Real-Time Polymerase Chain Reaction; Receptor, Angiotensin, Type 1; Tetrazoles; Up-Regulation; Valine; Valsartan | 2012 |
[Hyperkalemia. Main symptoms: muscle weakness, cardiac arrhythmias].
Topics: Arrhythmias, Cardiac; Drug Therapy, Combination; Electrocardiography; Heart Failure; Humans; Hyperkalemia; Hypertension; Male; Middle Aged; Muscle Weakness; Spironolactone; Tetrazoles; Valine; Valsartan | 2004 |